Multicomplex Pharmacophore Modeling of Estrogen Receptors Suggests the Probable Repurposing of Procaterol as an Antiproliferative Agent Against Breast Cancer Cells
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27010463 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Luis Heriberto Vazquez-Mendoza und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica (Laboratory for the Design and Development of New Drugs and Biotech…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Breast Neoplasms, Drug Repositioning, Estrogen Receptor alpha. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaría de Ciencia Tecnología e Innovación, Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI) México, Instituto Politécnico.
Abstract (Originalsprache)
Breast cancer (BC) is a malignant tumor that develops in the mammary gland due to uncontrolled cell proliferation. Estrogen receptor (ER) signaling, mediated by 17β-estradiol (E2), plays a crucial role in regulating cell proliferation, differentiation, and survival. Specifically, the binding of E2 to the estrogen receptor alpha (ERα) increases cell proliferation. Conversely, selective estrogen receptor beta (ERβ) agonists inhibit cancer cell proliferation by suppressing the expression of oncogenes, making ERβ an important therapeutic target. Given the urgent need for targeted and effective therapies for BC, we implemented a strategy based on multicomplex pharmacophores modeling of ERβ (MPMERβ) and ERα (MPMERα), performing a virtual cross-screening of databases of clinically approved and experimental drugs to identify those with high affinity and stereoelectronic complementarity with the ERβ agonist pharmacophore hypothesis. The implementation of a chemoinformatic strategy enabled the identification of Sobetirome, Labetalol, and Procaterol as molecular hits on the ERβ pharmacophore map. Procaterol showed the most significant antiproliferative activity in vitro assays, with IC50 values of 21.26 and 36.10 µM in MCF-7 and MDA-MB-231, respectively. It is imperative to note that these findings require experimental validation of the ERβ activation pathways to strengthen the possible therapeutic repurposing of the drugs selected through our in silico approach. Finally, this strategy not only facilitates drug repurposing under in silico simulation but also provides valuable information for the rational design of new drugs against BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica (Laboratory for the Design and Development of New Drugs and Biotechnological Innovation), Escuela Superior de Medicina del Instituto Poli…
- Unidad de Bioquímica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City 14080, Mexico.
- Ecole Nationale Supérieure de Technologie des Biomolécules de Bordeaux (ENSTBB), Université de Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, F-33600 Pessac, France.
- División de Biología Molecular, Instituto Potosino de Investigación Científica y Tecnológica (DBM-IPICYT), y Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI), San Luis Potosí 78216, Mexico.
- Investigadoras e Investigadores por México SECIHTI -Sección de Estudios de Posgrado e Investigación de la Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Salvador Díaz Mirón S/N, Casco d…
ORCID-Profile: Luis Heriberto Vazquez-Mendoza, Humberto L Mendoza-Figueroa, Nadia Judith Jacobo-Herrera, Norbert Bakalara, Daphne Edith González-Juárez, José Correa-Basurto, Juan Benjamín García-Vázquez
Förderung
- Secretaría de Ciencia Tecnología e Innovación
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI) México
- Instituto Politécnico
- SECIHTI
- Bordeaux, France
- Instituto Politécnico Nacional (SIP-IPN), México
Zitieren
APA
Vazquez-Mendoza, L. H., Mendoza-Figueroa, H. L., Jacobo-Herrera, N. J., Bakalara, N., González-Juárez, D. E., Correa-Basurto, J., & García-Vázquez, J. B. (2026). Multicomplex Pharmacophore Modeling of Estrogen Receptors Suggests the Probable Repurposing of Procaterol as an Antiproliferative Agent Against Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010463
Vancouver
Vazquez-Mendoza LH, Mendoza-Figueroa HL, Jacobo-Herrera NJ, Bakalara N, González-Juárez DE, Correa-Basurto J, et al. Multicomplex Pharmacophore Modeling of Estrogen Receptors Suggests the Probable Repurposing of Procaterol as an Antiproliferative Agent Against Breast Cancer Cells. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27010463
BibTeX
@article{VazquezMendoza2026,
author = {Vazquez-Mendoza, Luis Heriberto and Mendoza-Figueroa, Humberto L and Jacobo-Herrera, Nadia Judith and Bakalara, Norbert and González-Juárez, Daphne Edith and Correa-Basurto, José and García-Vázquez, Juan Benjamín},
title = {Multicomplex Pharmacophore Modeling of Estrogen Receptors Suggests the Probable Repurposing of Procaterol as an Antiproliferative Agent Against Breast Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27010463}
}
EUVIMED